Abstract

Our center represents a coordinated effort to utilize available knowledge and generate new scientific information in the fields of biochemical pharmacology, drug development, tumor biology, and clinical oncology pharmacology, with direct and practical relevance for use in man. A primary objective of the investigators participating in these studies is to achieve interdigitation of fundamental biochemical, pharmacological and biological concepts with the clinical problems presented by individuals afflicted with cancer and related disorders. A salient feature of the proposed program is the collaborative interdisciplinary approach that will result in an efficient mechanism for translating basic scientific insormation, through clinical investigators, to practicing physicians, as well as provide an effective feedbasck from the clinic to the laboratory.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013943-13
Application #
3101353
Study Section
Cancer Center Support Grant Review Committee (CCS)
Project Start
1979-08-01
Project End
1990-02-28
Budget Start
1985-03-01
Budget End
1986-02-28
Support Year
13
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
Roger Williams Hospital
Department
Type
DUNS #
City
Providence
State
RI
Country
United States
Zip Code

  Publications

Trunzo, Joseph J; Pinto, Bernardine M (2003) Social support as a mediator of optimism and distress in breast cancer survivors. J Consult Clin Psychol 71:805-11
Pinto, Bernardine M; Trunzo, Joseph J; Reiss, Philip et al. (2002) Exercise participation after diagnosis of breast cancer: trends and effects on mood and quality of life. Psychooncology 11:389-400
Wanebo, H J; Belliveau, J F (1999) A pharmacokinetic model and the clinical pharmacology of cis-platinum, 5-fluorouracil and mitomycin-C in isolated pelvic perfusion. Cancer Chemother Pharmacol 43:427-34
Oguey, D; Dumenco, L L; Pierce, R H et al. (1996) Analysis of the tumorigenicity of the X gene of hepatitis B virus in a nontransformed hepatocyte cell line and the effects of cotransfection with a murine p53 mutant equivalent to human codon 249. Hepatology 24:1024-33
Elenitoba-Johnson, K S; Medeiros, L J; Khorsand, J et al. (1996) P53 expression in Reed-Sternberg cells does not correlate with gene mutations in Hodgkin's disease. Am J Clin Pathol 106:728-38
Davol, P; Frackelton Jr, A R (1996) The mitotoxin, basic fibroblast growth factor-saporin, effectively targets human prostatic carcinoma in an animal model. J Urol 156:1174-9
Wolf, D A; Wang, S; Panzica, M A et al. (1996) Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 56:5012-22
Cheng, J C; Frackelton Jr, A R; Bearer, E L et al. (1995) Changes in tyrosine-phosphorylated p190 and its association with p120 type I and p100 type II rasGAPs during myelomonocytic differentiation of human leukemic cells. Cell Growth Differ 6:139-48
Dumenco, L; Oguey, D; Wu, J et al. (1995) Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. Hepatology 22:1279-88
Lee, S E; Pulaski, C R; He, D M et al. (1995) Isolation of mammalian cell mutants that are X-ray sensitive, impaired in DNA double-strand break repair and defective for V(D)J recombination. Mutat Res 336:279-91

Showing the most recent 10 out of 34 publications